Sign in
Taking people in United StatesPhase 2

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Key facts

Who runs it
Northside Hospital, Inc.
Where
Atlanta, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
9 Sept 2016
Expected to end
31 Aug 2028
Type of study
Interventional
Treatments tested
  • Fludarabine
  • Cyclophosphamide
  • Total Body Irradiation
  • Rabbit ATG
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with severe aplastic anemia who have a family member who can donate bone marrow with a half-similar tissue type.

Age
1 Year to 75 Years. The record says up to 65 years for previously treated patients and up to 75 years for previously treated patients (as written in the record).
Sex
All sexes can join.
Disease stage
Severe aplastic anemia. Blood tests must show 2 of 3: <500 PMN/mm3, <20,000 platelets, absolute reticulocyte count <40,000/microL. Bone marrow must be markedly hypocellular (<25% of normal cellularity), or moderately hypocellular with 70% non-myeloid precursors. Daily activity score KPS >= 70%.
Earlier treatment
People who had a prior allogeneic transplant (cells from another person) cannot join.
Biomarker or test result
A related donor sharing 3/6 - 5/6 of the HLA-A, B, DR tissue markers is needed. The donor must have a negative HLA cross-match test in the host vs. graft direction.

Main reasons for not taking part

  • Poor heart function (LVEF <40%)
  • Poor lung function (FEV1 & FVC <50% predicted)
  • Poor liver function (bili >= 2mg/dL)
  • Poor kidney function (creatinine >= 2.0mg/dL (177 µmol/L) or creatinine clearance <40mL/min)
  • Prior allogeneic transplant

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction
  • Age <= 65 years for previously treated and <= 75 years for previously treated patients
  • KPS >= 70%
  • Aplastic Anemia that meets the following criteria:; Peripheral Blood (must fulfill 2 of 3):
  • <500 PMN/mm3
  • <20,000 platelets
  • absolute reticulocyte count <40,000/microL; Bone Marrow (must be either):
  • markedly hypocellular (<25% of normal cellularity)
  • moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above

Who cannot take part

  • prior allogeneic transplant
  • poor cardiac function (LVEF <40%)
  • poor renal function (creatinine >= 2.0mg/dL or creatinine clearance <40mL/min)
  • poor pulmonary function (FEV1 \& FVC <50% predicted)
  • poor liver function (bili >= 2mg/dL)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 75 years old?

Where in United States

  • Blood and Marrow Transplant Group of GeorgiaAtlanta, United StatesContact: Melhem Solh, MDTaking people
  • Northside HospitalAtlanta, United StatesContact: Melhem Solh, MDTaking people

About the trial

What the trial wants to find out

Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.

The group in the trial

  • Flu/Cy/TBITreatment being tested

    Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 \& 4.

    Treatment: Fludarabine, Cyclophosphamide, Total Body Irradiation, and Rabbit ATG

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT02828592, who can take part
Record updated
14 October 2026